Cytokeratin 8 Antibody (Highly Pure)

Product Description

Cytokeratin 8 Antibody
Catalog number: B2010439
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 uL
Molecular Weight or Concentration: 150 kDa
Supplied as: Solution
Appearance: Clear Solution
Applications: highly specific monoclonal antibody to human CK8 (Cytokeratin-8).
Storage: -20C
Keywords: Cytokeratin-8 antibody
Grade: Biotechnology grade. All solid components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, Tokuda M,
Hojo S, Okada H, Takahara J. Detection of anti-cytokeratin 8 antibody in the
serum of patients with cryptogenic fibrosing alveolitis and pulmonary fibrosis
associated with collagen vascular disorders. Thorax. 1998 Nov;53(11):969-74.

2: Bozza WP, Zhang Y, Zhang B. Cytokeratin 8/18 protects breast cancer cell
lines from TRAIL-induced apoptosis. Oncotarget. 2018 May 1;9(33):23264-23273.

3: Hsu JD, Yao CC, Lee MY, Kok LF, Wang PH, Tyan YS, Han CP. True cytokeratin
8/18 immunohistochemistry is of no use in distinguishing between primary
endocervical and endometrial adenocarcinomas in a tissue microarray study. Int J
Gynecol Pathol. 2010 May;29(3):282-9.

4: Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, Tokuda M,
Hojo S, Bandou S, Ueda Y, Takahara J. Circulating cytokeratin 8:anti-cytokeratin
8 antibody immune complexes in sera of patients with pulmonary fibrosis.
Respiration. 2000;67(4):397-401.

5: Lin WL, Chen FL, Kuo JF, Lee MY, Han CP. Cytokeratin 8/18 monoclonal antibody
was dissimilar to anti-cytokeratin CAM 5.2.–a comment on: “Discovery of two
novel EWSR1/ATF1 transcripts in four chimerical transcripts-expressing clear
cell sarcoma and their quantitative evaluation, Experimental and Molecular
Pathology 90(2): 194-200, April 2011”. Exp Mol Pathol. 2011 Aug;91(1):323-4.

6: Yao CC, Tseng SW, Han CP. Monoclonal antibody CAM5.2 can detect the
cytokeratin 8, not cytokeratin 18. Comment on: “Occult disseminated tumor cells
in lymph nodes of patients with gastric carcinoma. A critical appraisal of
assessment and relevance. Langenbecks Arch Surg. 2009 Jan; 394(1): 105-113.”.
Langenbecks Arch Surg. 2010 Mar;395(3):291-2.

7: Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow
F, Damon LJ, Lee D, Parks M, Dicecca R, Greenberg M, Kattermann KE, Riley AK,
Fintelmann FJ, Rizzo C, Piotrowska Z, Shaw AT, Gainor JF, Sequist LV, Niederst
MJ, Engelman JA, Benes CH. Primary Patient-Derived Cancer Cells and Their
Potential for Personalized Cancer Patient Care. Cell Rep. 2017 Dec
12;21(11):3298-3309.

8: Koshi R, Mustafa Y, Perry ME. Vimentin, cytokeratin 8 and cytokeratin 18 are
not specific markers for M-cells in human palatine tonsils. J Anat. 2001
Dec;199(Pt 6):663-74.
9: Han CP, Huang YC, Lee MY, Chen EY, Wang PH, Tzeng SL, Chen CK. Anti-
cytokeratin CAM5.2 should not be mistaken for cytokeratin 8/18 monoclonal
antibody: comment on “spindle cell squamous cell carcinoma not expressing
stratified but simple epithelial cytokeratin: Efficacy of simple epithelial
cytokeratin immunoreactivity” (Tokuriki A, Kiyohara T, Kouraba S, Kumakiri M,
Journal of Dermatology 2012; 39: 72-75). J Dermatol. 2012 Dec;39(12):1110.

Products Related to Cytokeratin 8 Antibody : Antibodies